Institution
Paul Sabatier University
Education•Toulouse, France•
About: Paul Sabatier University is a education organization based out in Toulouse, France. It is known for research contribution in the topics: Population & Catalysis. The organization has 15431 authors who have published 23386 publications receiving 858364 citations.
Topics: Population, Catalysis, Context (language use), Adipose tissue, Electron
Papers published on a yearly basis
Papers
More filters
••
TL;DR: It is shown that new nanostructured electrode materials and matching electrolytes are required to maximize the amount of energy and speed of delivery, and different manufacturing methods will be needed to meet the requirements of the future generation of electronic devices.
Abstract: Electrochemical capacitors can store electrical energy harvested from intermittent sources and deliver energy quickly, but their energy density must be increased if they are to efficiently power flexible and wearable electronics, as well as larger equipment. This Review summarizes progress in the field of materials for electrochemical capacitors over the past decade as well as outlines key perspectives for future research. We describe electrical double-layer capacitors based on high-surface-area carbons, pseudocapacitive materials such as oxides and the two-dimensional inorganic compounds known as MXenes, and emerging microdevices for the Internet of Things. We show that new nanostructured electrode materials and matching electrolytes are required to maximize the amount of energy and speed of delivery, and different manufacturing methods will be needed to meet the requirements of the future generation of electronic devices. Scientifically justified metrics for testing, comparison and optimization of various kinds of electrochemical capacitors are provided and explained.
952 citations
••
TL;DR: Dabrafenib plus trametinib represents a new therapy with clinically meaningful antitumour activity and a manageable safety profile in patients with previously untreated BRAFV600E-mutant NSCLC.
Abstract: Summary Background BRAF mutations act as an oncogenic driver via the mitogen-activated protein kinase (MAPK) pathway in non-small cell lung cancer (NSCLC). BRAF inhibition has shown antitumour activity in patients with BRAF V600E -mutant NSCLC. Dual MAPK pathway inhibition with BRAF and MEK inhibitors in BRAF V600E -mutant NSCLC might improve efficacy over BRAF inhibitor monotherapy based on observations in BRAF V600 -mutant melanoma. We aimed to assess the antitumour activity and safety of dabrafenib plus trametinib in patients with BRAF V600E -mutant NSCLC. Methods In this phase 2, multicentre, non-randomised, open-label study, we enrolled adult patients (aged ≥18 years) with pretreated metastatic stage IV BRAF V600E -mutant NSCLC who had documented tumour progression after at least one previous platinum-based chemotherapy and had had no more than three previous systemic anticancer therapies. Patients with previous BRAF or MEK inhibitor treatment were ineligible. Patients with brain metastases were allowed to enrol only if the lesions were asymptomatic, untreated (or stable more than 3 weeks after local therapy if treated), and measured less than 1 cm. Enrolled patients received oral dabrafenib (150 mg twice daily) plus oral trametinib (2 mg once daily) in continuous 21-day cycles until disease progression, unacceptable adverse events, withdrawal of consent, or death. The primary endpoint was investigator-assessed overall response, which was assessed by intention to treat in the protocol-defined population (patients who received second-line or later treatment); safety was also assessed in this population and was assessed at least once every 3 weeks, with adverse events, laboratory values, and vital signs graded according to the Common Terminology Criteria for Adverse Events version 4.0. The study is ongoing but no longer recruiting patients. This trial is registered with ClinicalTrials.gov, number NCT01336634. Findings Between Dec 20, 2013, and Jan 14, 2015, 59 patients from 30 centres in nine countries across North America, Europe, and Asia met eligibility criteria. Two patients who had previously been untreated due to protocol deviation were excluded; thus, 57 eligible patients were enrolled. 36 patients (63·2% [95% CI 49·3–75·6]) achieved an investigator-assessed overall response. Serious adverse events were reported in 32 (56%) of 57 patients and included pyrexia in nine (16%), anaemia in three (5%), confusional state in two (4%), decreased appetite in two (4%), haemoptysis in two (4%), hypercalcaemia in two (4%), nausea in two (4%), and cutaneous squamous cell carcinoma in two (4%). The most common grade 3–4 adverse events were neutropenia in five patients (9%), hyponatraemia in four (7%), and anaemia in three (5%). Four patients died during the study from fatal adverse events judged to be unrelated to treatment (one retroperitoneal haemorrhage, one subarachnoid haemorrhage, one respiratory distress, and one from disease progression that was more severe than typical progression, as assessed by the investigator). Interpretation Dabrafenib plus trametinib could represent a new targeted therapy with robust antitumour activity and a manageable safety profile in patients with BRAF V600E -mutant NSCLC. Funding GlaxoSmithKline.
943 citations
••
TL;DR: A complete set of comparison indices is proposed in the framework of Zadeh's possibility theory and it is shown that generally four indices enable one to completely describe the respective locations of two fuzzy numbers.
938 citations
••
TL;DR: It is argued that feedback connections are the best candidates for rapid long-distance interconnections between neurons coding for distant regions in the visual field.
938 citations
••
TL;DR: An extensive survey on fuzzy set-theoretic operations is provided, and the relevance of the theory of functional equations in the axiomatical construction of classes of such operations and the derivation of functional representations is emphasized.
932 citations
Authors
Showing all 15486 results
Name | H-index | Papers | Citations |
---|---|---|---|
Yury Gogotsi | 171 | 956 | 144520 |
Tobin J. Marks | 159 | 1621 | 111604 |
L. Montier | 138 | 403 | 97094 |
Jean-Paul Kneib | 138 | 805 | 89287 |
Olivier Forni | 137 | 548 | 95819 |
J. Aumont | 131 | 299 | 95006 |
Julian I. Schroeder | 120 | 315 | 50323 |
Bruno Vellas | 118 | 1011 | 70667 |
Christopher G. Goetz | 116 | 651 | 59510 |
Didier Dubois | 113 | 742 | 54741 |
Alain Dufresne | 111 | 358 | 45904 |
Henri Prade | 108 | 917 | 54583 |
Louis Bernatchez | 106 | 568 | 35682 |
Walter Wahli | 105 | 365 | 49372 |
Patrice D. Cani | 100 | 370 | 49523 |